TY - JOUR
T1 - Minimum information about tolerogenic antigen-presenting cells (MITAP): A first step towards reproducibility and standardisation of cellular therapies
AU - Lord, Phillip
AU - Spiering, Rachel
AU - Aguillon, Juan C.
AU - Anderson, Amy E.
AU - Appel, Silke
AU - Benitez-Ribas, Daniel
AU - ten Brinke, Anja
AU - Broere, Femke
AU - Cools, Nathalie
AU - Cuturi, Maria Cristina
AU - Diboll, Julie
AU - Geissler, Edward K.
AU - Giannoukakis, Nick
AU - Gregori, Silvia
AU - Marieke van Ham, S.
AU - Lattimer, Staci
AU - Marshall, Lindsay
AU - Harry, Rachel A.
AU - Hutchinson, James A.
AU - Isaacs, John D.
AU - Joosten, Irma
AU - van Kooten, Cees
AU - de Cerio, Ascension Lopez Diaz
AU - Nikolic, Tatjana
AU - Oral, Haluk Barbaros
AU - Sofronic-Milosavljevic, Ljiljana
AU - Ritter, Thomas
AU - Riquelme, Paloma
AU - Thomson, Angus W.
AU - Trucco, Massimo
AU - Vives-Pi, Marta
AU - Martinez-Caceres, Eva M.
AU - Hilkens, Catharien M.U.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - © 2016 Lord et al. Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.
AB - © 2016 Lord et al. Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.
KW - Antigen-presenting cells
KW - Autoimmune disease
KW - Cell therapy
KW - Minimum information model
KW - Regulatory macrophages
KW - Reporting guidelines
KW - Tolerogenic dendritic cells
KW - Transplantation
U2 - 10.7717/peerj.2300
DO - 10.7717/peerj.2300
M3 - Article
SN - 2167-8359
VL - 2016
JO - PeerJ
JF - PeerJ
IS - 8
M1 - e2300
ER -